Lidocaine Patch (5%) is No More Potent than Placebo in Treating Chronic Back Pain When Tested in a Randomised Double Blind Placebo Controlled Brain Imaging Study
| Autor: | Elle L Parks, A. Vania Apkarian, Thomas J. Schnitzer, Lejian Huang, Mona L. Chanda, Marwan N. Baliki, Javeria A. Hashmi |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Male
Lidocaine fmri Pain medicine Transdermal Patch Neuroimaging Chronic pain Placebo Topical analgesic 03 medical and health sciences Cellular and Molecular Neuroscience 0302 clinical medicine Double-Blind Method 030202 anesthesiology lcsh:Pathology medicine Back pain Humans Brain Mapping business.industry Research Brain Middle Aged Lidocaine Patch Placebo Effect medicine.disease Magnetic Resonance Imaging 3. Good health Clinical trial Anesthesiology and Pain Medicine Complex regional pain syndrome Back Pain Anesthesia Neuropathic pain Molecular Medicine Female medicine.symptom business 030217 neurology & neurosurgery lcsh:RB1-214 medicine.drug |
| Zdroj: | Molecular Pain Molecular Pain, Vol 8, Iss 1, p 29 (2012) |
| ISSN: | 1744-8069 |
| DOI: | 10.1186/1744-8069-8-29 |
| Popis: | Background: The 5% Lidocaine patch is used for treating chronic neuropathic pain conditions such as chronic back pain (CBP), diabetic neuropathy and complex regional pain syndrome, but is effective in a variable proportion of patients. Our lab has reported that this treatment reduces CBP intensity and associated brain activations when tested in an open labelled preliminary study. Notably, effectiveness of the 5% Lidocaine patch has not been tested against placebo for treating CBP. In this study, effectiveness of the 5% Lidocaine patch was compared with placebo in 30 CBP patients in a randomised double-blind study where 15 patients received 5% Lidocaine patches and the remaining patients received placebo patches. Functional MRI was used to identify brain activity for fluctuations of spontaneous pain, at baseline and at two time points after start of treatment (6 hours and 2 weeks). Results: There was no significant difference between the treatment groups in either pain intensity, sensory and affective qualities of pain or in pain related brain activation at any time point. However, 50% patients in both the Lidocaine and placebo arms reported a greater than 50% decrease in pain suggesting a marked placebo effect. When tested against an untreated CBP group at similar time points, the patch treated subjects showed significantly greater decrease in pain compared to the untreated group (n = 15). Conclusions: These findings suggest that although the 5% Lidocaine is not better than placebo in its effectiveness for treating pain, the patch itself induces a potent placebo effect in a significant proportion of CBP patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink